Shattuck Labs (STTK)
Develops DR3-blocking antibodies for inflammatory and immune-mediated diseases.
BlackRock Inc. Invests $27.32 Million in Shattuck Labs, Inc. $STTK
BlackRock Inc. purchased a new stake in Shattuck Labs, Inc. (NASDAQ: STTK) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 3,935,810 shares of the company's stock, valued at approximately $27,315,000. BlackRock Inc. owned about 5.13% of Shattuck Labs as of its
What Shattuck Labs Stock Topped the Market on Monday
One of them initiated coverage. The company has a very promising lead drug candidate.
Wall Street Analysts Believe Shattuck Labs (STTK) Could Rally 85.31%: Here's is How to Trade
The consensus price target hints at an 85.3% upside potential for Shattuck Labs (STTK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Why Shattuck Labs Stock Flew Nearly 5% Higher on Friday
He was encouraged by the progress of the company's SL-325. This, the biotech's lead drug candidate, is about to enter Phase 2 clinical testing.
This Shattuck Labs Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Shattuck Labs, Inc. (NASDAQ:STTK) Receives $11.00 Average PT from Brokerages
Shattuck Labs, Inc. (NASDAQ: STTK - Get Free Report) has received an average recommendation of "Moderate Buy" from the ten ratings firms that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation and nine have assigned a buy recommendation to the company. The average 12-month target price among
Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering
AUSTIN, Texas and DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced the pricing of its previously announced a public offering of 10,879,376 shares of its common stock at a public offering price per share of $4.00 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 7,870,624 shares of its common stock at a public offering price of $3.9999 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.0001 per share and are exercisable immediately. The aggregate gross proceeds to Shattuck from the offering are expected to be approximately $75 million before deducting underwriting discounts and commissions and other offering expenses payable by Shattuck, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on June 11, 2026, subject to the satisfaction of customary closing conditions. In addition, Shattuck has granted the underwriters an option for a period of 30 days to purchase up to an additional 2,812,500 shares of its common stock at the public offering price, less underwriting discounts and commissions.
Shattuck Labs, Inc. Announces Proposed Public Offering
AUSTIN, Texas and DURHAM, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced that it has commenced a public offering of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, Shattuck expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock at the public offering price, less underwriting discounts and commissions. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the securities are being offered by Shattuck.
Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update
AUSTIN, Texas and DURHAM, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3-blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced it has received notices to exercise totaling approximately 50.6 million common stock warrants to date, representing approximately 96% of the warrants issued in the Company's August 4, 2025 private placement.
Shattuck Labs, Inc. (STTK) Discusses Phase I Results for DR3 Blocking Antibody SL-325 and Pipeline Update Transcript
Shattuck Labs, Inc. (STTK) Discusses Phase I Results for DR3 Blocking Antibody SL-325 and Pipeline Update Transcript
Why Is Shattuck Labs Stock Trading Lower On Monday?
Shattuck Labs Inc. (NASDAQ:STTK) stock is down on Monday following news regarding its lead drug candidate, SL-325.
Shattuck Labs Announces Phase 1 Results for SL-325
AUSTIN, TX and DURHAM, NC, June 08, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced data from its Phase 1 clinical trial of SL-325, Shattuck's lead DR3 blocking antibody candidate.
Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8
AUSTIN, Texas and DURHAM, N.C., June 05, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3-blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced that it will host an investor call and webcast on Monday, June 8, 2026 at 8:00 a.m. ET to present comprehensive Phase 1 clinical data for SL-325, including safety, tolerability, pharmacokinetics, receptor occupancy, pharmacodynamic and immunogenicity results and provide a pipeline update.
Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business Highlights
AUSTIN, Texas and DURHAM, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today reported financial results for the first quarter ended March 31, 2026 and provided recent business highlights.
Aberdeen Group plc Buys 436,673 Shares of Shattuck Labs, Inc. $STTK
Aberdeen Group plc increased its stake in Shattuck Labs, Inc. (NASDAQ: STTK) by 462.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 531,177 shares of the company's stock after purchasing an additional 436,673 shares during the period. Aberdeen Group plc owned approximately 0.84%
Analysts Set Shattuck Labs, Inc. (NASDAQ:STTK) Target Price at $10.50
Shattuck Labs, Inc. (NASDAQ: STTK - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the eight ratings firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have given a buy recommendation to the company.
Why Shattuck Labs Stock Soared More Than 53% Higher This Week
The biotech published its final earnings report and business covering 2025. It posted a slightly narrower-than-expected net loss for the fourth quarter.
Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights
AUSTIN, Texas and DURHAM, N.C., March 05, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today reported financial results for the fourth quarter and full year ended December 31, 2025 and provided recent business highlights.
Shattuck Labs Announces Participation in Upcoming March Investor Conferences
AUSTIN, TX and DURHAM, NC, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3-blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced that company management will present at and participate in the following upcoming investor conferences: Conference Details TD Cowen 46 th Annual Health Care Conference Format: Corporate presentation and one-on-one meetings Presenter: Taylor Schreiber, M.D., Ph.D., Chief Executive Officer Presentation Date: March 2, 2026 Time: 9:10 AM ET Location: Boston, MA Webcast link: HERE Leerink Partners 2026 Global Health Care Conference Format: One-on-one investor meetings Participant: Taylor Schreiber, M.D.
Shattuck Labs, Inc. (NASDAQ:STTK) Receives $6.20 Consensus PT from Analysts
Shattuck Labs, Inc. (NASDAQ: STTK - Get Free Report) has earned a consensus rating of "Hold" from the seven research firms that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the